

Janet E Pope

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7889158/janet-e-pope-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

540
papers

25,699
citations

75
h-index

142
g-index

615
ext. papers

31,520
ext. citations

4.9
avg, IF

7.04
L-index

#	Paper	IF	Citations
540	Immunosuppression use in early systemic sclerosis may be increasing over time.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 33-41	2.3	
539	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program.. <i>Pilot and Feasibility Studies</i> , 2022 , 8, 45	1.9	0
538	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1606-1616	4.7	12
537	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021 , 22, 856	2.8	1
536	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. <i>Lancet Rheumatology</i> , 2021 , 3, e844-e854	14.2	2
535	Feminization of the Rheumatology Workforce: A Longitudinal Evaluation of Patient Volumes, Practice Sizes, and Physician Remuneration. <i>Journal of Rheumatology</i> , 2021 , 48, 1090-1097	4.1	3
534	Arthritis in Systemic Sclerosis. <i>In Clinical Practice</i> , 2021 , 339-362	0	
533	A meta-analysis of the epidemiology of giant cell arteritis across time and space. <i>Arthritis Research and Therapy</i> , 2021 , 23, 82	5.7	7
532	Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2021 , 38, 2750-2756 ⁰	4.1	0
531	Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study. <i>Rheumatology</i> , 2021 ,	3.9	1
530	Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. <i>Journal of Rheumatology</i> , 2021 , 48, 1427-1434	4.1	0
529	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021 , 48, 1698-1717	4.1	2
528	Pertinence des tests de laboratoire dans le diagnostic des rhumatismes inflammatoires chez des patients nouvellement orientés vers un rhumatologue. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021 , 88, 208-215	0.1	
527	Osteoporosis and osteonecrosis in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , 2021 , 28, 3-11	0.2	0
526	Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). <i>RMD Open</i> , 2021 , 7,	5.9	2
525	Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2021 , 48, 25-34	4.1	16
524	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50

523	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021 , 48, 852-858	4.1	4
522	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021 , 140, 110314	4.1	3
521	Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI). <i>Rheumatology</i> , 2021 , 60, 717-727	3.9	
520	Health Assessment Questionnaire at One Year Predicts All-Cause Mortality in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 197-202	9.5	5
519	Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 53-60	9.5	5
518	Metrics and Outcomes of Systemic Lupus Erythematosus in Clinical Practice 2021 , 391-402		
517	Scleroderma epidemiology update. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 122-127	5.3	5
516	Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2197-2207	7.4	7
515	C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 219-229	5.3	19
514	Increased mortality for individuals with Giant Cell Arteritis: a population-based study. <i>Arthritis Care and Research</i> , 2021 ,	4.7	1
513	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	12
512	Evaluation of Rheumatology Workforce Supply Changes in Ontario, Canada, from 2000 to 2030. <i>Healthcare Policy</i> , 2021 , 16, 119-134	1.1	4
511	Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis. <i>Rheumatology and Therapy</i> , 2021 , 8, 1383-1391	4.4	0
510	Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database. <i>Current Rheumatology Reviews</i> , 2021 , 17, 349-359	1.6	
509	Current and future status of JAK inhibitors. <i>Lancet, The</i> , 2021 , 398, 803-816	4.0	17
508	Pain and Self-Efficacy Among Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Nursing Research</i> , 2021 , 70, 334-343	1.9	2
507	Counselling patients for return to work on immunosuppression: practices of Canadian specialists during the COVID-19 pandemic. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 874-878	2.2	0
506	Management of Fatigue in Rheumatoid Arthritis. <i>RMD Open</i> , 2020 , 6,	5.9	16

505	European consensus statements for interstitial lung disease in systemic sclerosis. <i>Lancet Rheumatology, The</i> , 2020 , 2, e318-e319	14.2	
504	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. <i>Autoimmunity Reviews</i> , 2020 , 19, 102595	13.6	22
503	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). <i>Arthritis Research and Therapy</i> , 2020 , 22, 132	5.7	4
502	Appropriateness of laboratory tests in the diagnosis of inflammatory rheumatic diseases among patients newly referred to rheumatologists. <i>Joint Bone Spine</i> , 2020 , 87, 588-595	2.9	2
501	Giant Calcinosis in Dermatomyositis and Scleroderma Overlap. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1236	9.5	0
500	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis: reply. <i>Rheumatology</i> , 2020 , 59, 1783-1784	3.9	0
499	Encounters with Rheumatologists in a Publicly Funded Canadian Healthcare System: A Population-based Study. <i>Journal of Rheumatology</i> , 2020 , 47, 468-476	4.1	5
498	The future of treatment in systemic sclerosis: can we design better trials?. <i>Lancet Rheumatology, The</i> , 2020 , 2, e185-e194	14.2	8
497	An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1421-1427	5.3	3
496	What Does the COVID-19 Pandemic Mean for Rheumatology Patients?. <i>Current Treatment Options in Rheumatology</i> , 2020 , 6, 1-4	1.3	23
495	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	2.4	85 ¹
494	Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. <i>Rheumatology</i> , 2020 , 59, 568-574	3.9	5
493	The Canadian Consensus Working Group's Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. <i>Contemporary Cardiology</i> , 2020 , 137-150	0.1	
492	Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma patient-centred Intervention Network (SPIN) Cohort Study. <i>BMJ Open</i> , 2020 , 10, e037639	3	2
491	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020 , 9, e16799	2	3
490	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020 , 7, S222-S227	1.7	9
489	Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2020 , 39, 963-965	3.9	1
488	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020 , 135, 110132	4.1	13

487	Immunoglobulin G-related disease as a mimicker of granulomatosis with polyangiitis: a case report. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 163-164	1.9	
486	Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 1715-1724	3.9	4
485	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.. <i>Lancet Rheumatology, The</i> , 2020 , 2, e743-e753	14.2	13
484	Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102659	13.6	10
483	A cluster of non-tuberculosis mycobacterial infections in patients with connective tissue diseases. <i>Medicina Clinica</i> , 2020 , 154, 468-469	1	0
482	Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). <i>Autoimmunity Reviews</i> , 2020 , 19, 102602	13.6	4
481	An Update of Outcome Measures in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 110-133	4.7	
480	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. <i>Journal of Psychosomatic Research</i> , 2020 , 139, 110262	4.1	9
479	The frequency of uveitis in patients with adult versus childhood spondyloarthritis. <i>RMD Open</i> , 2020 , 6,	5.9	3
478	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine, the</i> , 2020 , 8, 963-974	35.1	112
477	Comment on: Incidence and prevalence of giant cell arteritis in Ontario, Canada: reply. <i>Rheumatology</i> , 2020 , 59, e123-e124	3.9	
476	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. <i>Arthritis Care and Research</i> , 2020 , 72, 1104-1111	4.7	7
475	Meta-Analysis of Treatment for Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2020 , 72, 1011-1021	4.7	9
474	Patient perception of disease burden in diffuse cutaneous systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 66-76	2.3	3
473	An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs. <i>Rheumatology</i> , 2020 , 59, 1522-1528	3.9	2
472	Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. <i>Rheumatology</i> , 2020 , 59, 398-406	3.9	8
471	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020 , 72, 125-136	9.5	92
470	Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2020 , 37, 2356-2372	4.1	20

469	Incidence and prevalence of giant cell arteritis in Ontario, Canada. <i>Rheumatology</i> , 2020 , 59, 3250-3258	3.9	6
468	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 618-625	2.4	30
467	Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. <i>Lancet Rheumatology</i> , 2019 , 1, e23-e34	14.2	13
466	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17
465	Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 102-110	2.3	5
464	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019 , 46, 751-754	4.1	14
463	Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2019 , 46, 532-538	4.1	23
462	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. <i>Rheumatology and Therapy</i> , 2019 , 6, 409-419	4.4	5
461	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1242-1248	2.4	18
460	Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Journal of Rheumatology</i> , 2019 , 46, 1605-1613	4.1	5
459	Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results. <i>Journal of Rheumatology</i> , 2019 , 46, 874-886	4.1	1
458	Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years. <i>ACR Open Rheumatology</i> , 2019 , 1, 73-82	3.5	8
457	A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. <i>Rheumatology</i> , 2019 ,	3.9	10
456	Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. <i>BMJ Open</i> , 2019 , 9, e024010	3	10
455	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 648-656	2.4	43
454	Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. <i>Immunotherapy</i> , 2019 , 11, 737-754	3.8	23
453	Association of Arthritis Onset with Influenza: Analysis of the Canadian Early Inflammatory Arthritis Cohort. <i>ACR Open Rheumatology</i> , 2019 , 1, 63-69	3.5	4
452	Evolving patterns of reactive arthritis. <i>Clinical Rheumatology</i> , 2019 , 38, 2083-2088	3.9	5

451	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 807-816	2.4	16
450	Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2019 , 71, 620-628	4.7	8
449	Raynaud's phenomenon-an update on diagnosis, classification and management. <i>Clinical Rheumatology</i> , 2019 , 38, 3317-3330	3.9	32
448	Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative-a rheumatoid arthritis cohort. <i>Journal of Clinical Epidemiology</i> , 2019 , 114, 95-103	5.7	3
447	The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2019 , 86, 685-690	2.9	16
446	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019 , 2, 149-152 ^{0.5}		2
445	How low can we go for continued dosing of rituximab in rheumatoid arthritis?. <i>Lancet Rheumatology, The</i> , 2019 , 1, e134-e135	14.2	
444	Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. <i>ACR Open Rheumatology</i> , 2019 , 1, 471-479	3.5	2
443	Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019 , 1, 535-541	3.5	6
442	OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS-RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL 2019 ,		1
441	OP0315 ACHIEVING A LOW DISEASE STATE WITHIN FIRST 3 MONTHS IN EARLY RHEUMATOID ARTHRITIS RESULTS IN LOWER FATIGUE OVER 5 YEARS 2019 ,		2
440	Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>BMJ Open</i> , 2019 , 9, e029542	3	1
439	A quarter of patients time their early rheumatoid arthritis onset differently than physicians. <i>RMD Open</i> , 2019 , 5, e000931	5.9	1
438	Planning for the Rheumatologist Workforce: Factors Associated With Work Hours and Volumes. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, 142-146	1.1	7
437	Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort. <i>ACR Open Rheumatology</i> , 2019 , 1, 614-619	3.5	3
436	Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. <i>Arthritis Research and Therapy</i> , 2019 , 21, 263	5.7	16
435	Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. <i>Arthritis Research and Therapy</i> , 2019 , 21, 272	5.7	16
434	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019 , 46, 166-175	4.1	8

433	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 50-74	1.6	58
432	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
431	Reply. <i>Arthritis and Rheumatology</i> , 2019 , 71, 834-835	9.5	
430	Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 467-474	4.1	19
429	A systematic review of viral exposures as a risk for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 587-596	5.3	18
428	Physician global assessments for disease activity in rheumatoid arthritis are all over the map!. <i>RMD Open</i> , 2018 , 4, e000578	5.9	4
427	Repeat Testing of Antibodies and Complements in Systemic Lupus Erythematosus: When Is It Enough?. <i>Journal of Rheumatology</i> , 2018 , 45, 827-834	4.1	8
426	Randomized Trials, Meta-Analyses, and Systematic Reviews: Using Examples from Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2018 , 44, 295-305	2.4	1
425	High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years. <i>Arthritis Care and Research</i> , 2018 , 70, 842-850	4.7	8
424	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. <i>Autoimmunity Reviews</i> , 2018 , 17, 267-275	13.6	15
423	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1646-1652	4.7	5
422	Mentoring women in medicine: a personal perspective. <i>Lancet, The</i> , 2018 , 391, 520-521	4.0	7
421	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 813-817	3.9	14
420	Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 456-464	4.1	12
419	Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>BMJ Open</i> , 2018 , 8, e018641	3	2
418	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>Disability and Rehabilitation</i> , 2018 , 40, 1997-2003	2.4	7
417	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 128-132	2.4	17
416	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 152-157	3.9	7

415	There is a need for new systemic sclerosis subset criteria. A content analytic approach. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 62-70	1.9	18
414	Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1448-1461	4.1	16
413	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>Advances in Therapy</i> , 2018 , 35, 1535-1563	4.1	40
412	The contemporary management of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 573-582	5.1	2
411	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018 , 57, 1623-1631	3.9	26
410	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 212-220	2.4	172
409	Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1185-1191	4.7	22
408	Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis. <i>Arthritis Care and Research</i> , 2018 , 70, 1245-1250	4.7	13
407	ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI). <i>RMD Open</i> , 2018 , 4, e000738	5.9	12
406	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1426-1439	4.1	33
405	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 249-252	2.3	25
404	Treatment Algorithms for Systemic Sclerosis According to Experts. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1820-1828	9.5	120
403	Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2018 , 45, 1462-1476	4.1	29
402	Flibanserin. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 256-260	1.3	3
401	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. <i>Arthritis Care and Research</i> , 2017 , 69, 124-132	4.7	13
400	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017 , 20, 99-106	7.4	3
399	The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. <i>Rheumatology</i> , 2017 , 56, 768-776	3.9	13
398	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 270-276	2.4	79

397	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017 , 3, e000371	5.9	19
396	Stand Up and Be Counted: Measuring and Mapping the Rheumatology Workforce in Canada. <i>Journal of Rheumatology</i> , 2017 , 44, 248-257	4.1	52
395	Novel treatment strategies in rheumatoid arthritis. <i>Lancet, The</i> , 2017 , 389, 2338-2348	4.0	407
394	Antifibrillar Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017 , 44, 799-805	4.1	14
393	Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. <i>Rheumatology</i> , 2017 , 56, 1144-1153	3.9	50
392	Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. <i>Rheumatology</i> , 2017 , 56, 1111-1122	3.9	7
391	Does the impact of board independence on large bank risks change after the global financial crisis?. <i>Journal of Corporate Finance</i> , 2017 , 44, 149-166	3.7	50
390	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1067-1077	9.5	91
389	Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 767-774	5.3	28
388	Connective tissue disease: Reflections on the EULAR recommendations for the treatment of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 134-136	8.1	3
387	The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. <i>Clinical Rheumatology</i> , 2017 , 36, 373-379	3.9	5
386	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4	171
385	Calcium channel blockers for primary and secondary Raynaud's phenomenon. <i>The Cochrane Library</i> , 2017 , 12, CD000467	5.2	17
384	Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2017 , 69, 737-741	4.7	2
383	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017 , 69, 362-375	9.5	125
382	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017 , 122 Suppl 1, S14-S17	4.1	24
381	Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 11-18	2.3	190
380	A randomized, single-blinded cross-over trial of ischemic preconditioning in Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 213-220	2.3	1

379	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 169-182	2.3	11
378	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 42-49	2.3	18
377	A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). <i>PLoS ONE</i> , 2017 , 12, e0189840	3.7	12
376	Stress in patients diagnosed with rheumatoid arthritis compared to chronic pain. <i>Rehabilitation Psychology</i> , 2017 , 62, 571-579	2.7	9
375	A Needs-Based Rheumatologist Education Program on Treating to Target in Psoriatic Arthritis and Spondyloarthritis: Insights and Challenges. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2017 , 07, 53-64	0.2	
374	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. <i>Rheumatology</i> , 2017 , 56, 581-588	3.9	11
373	CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1871-1878	9.5	43
372	Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 799-803	2.2	6
371	The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. <i>Clinical Rheumatology</i> , 2016 , 35, 759-63	3.9	16
370	Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. <i>Rheumatology</i> , 2016 , 55, 1751-62	3.9	22
369	Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician's Global Assessment of Disease Severity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016 , 43, 1510-8	4.1	8
368	Emerging drugs and therapeutics for systemic sclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 421-430	3.7	6
367	FRI0269 Diffuse Cutaneous Systemic Sclerosis (dcSSc) Referral and Diagnosis: Results of A Survey of Healthcare Providers. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 532.1-532	2.4	
366	AB0206 Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from The Ontario Best Practice Research Initiatives Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 967.3-968	2.4	
365	OP0173 How Much of A Barrier Is Excess Weight and Smoking for Achieving Sustained Remission in Early RA? Results from The Canadian Early Arthritis Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 121.2-121	2.4	
364	FRI0066 The 28-Joint Disease Activity Score (DAS28) Using C-Reactive Protein Yields Lower Thresholds Compared To Conventional DAS28 with Erythrocyte Sedimentation Rate in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 449.3-450	2.4	2
363	The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 364	2.8	3
362	Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. <i>Medicine (United States)</i> , 2016 , 95, e4713	1.8	36

361	Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women With Systemic Sclerosis: A Canadian Scleroderma Research Group Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1143-9	4.7	8
360	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016 , 68, 167-78	4.7	10
359	Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1704-1713	4.7	15
358	Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study. <i>Arthritis Care and Research</i> , 2016 , 68, 673-80	4.7	17
357	Development and Validation of the Body Concealment Scale for Scleroderma. <i>Arthritis Care and Research</i> , 2016 , 68, 1158-65	4.7	8
356	Reply. <i>Arthritis Care and Research</i> , 2016 , 68, 1385-6	4.7	
355	Measuring the Rheumatology Workforce in Canada: A Literature Review. <i>Journal of Rheumatology</i> , 2016 , 43, 1121-9	4.1	15
354	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016 , 18, 20	5.7	13
353	Severe myositis of the hip flexors after pre-operative chemoradiation therapy for locally advanced rectal cancer: case report. <i>BMC Cancer</i> , 2016 , 16, 243	4.8	6
352	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 299-311	9.5	69
351	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1003-8	2.4	35
350	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016 , 32, S35-65	3.8	138
349	Diagnosis and Management of Systemic Sclerosis: A Practical Approach. <i>Drugs</i> , 2016 , 76, 203-13	12.1	17
348	Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis Severity. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016 , 20, 221-7	1.6	37
347	Patient-Reported Outcome Measures in Systemic Sclerosis (Scleroderma). <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 301-16	2.4	13
346	The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. <i>Journal of Pain and Symptom Management</i> , 2016 , 52, 43-53	4.8	20
345	Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 327-34	3.9	11
344	How to Attract Trainees, a Pan-Canadian Perspective: Phase 1 of the "Training the Rheumatologists of Tomorrow" Project. <i>Journal of Rheumatology</i> , 2016 , 43, 788-98	4.1	5

343	A review of the effects of statins in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 698-705	5.3	17
342	PROMs for Systemic Sclerosis (Scleroderma) 2016 , 287-307		
341	Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression Over 24 Weeks. <i>Open Rheumatology Journal</i> , 2016 , 10, 49-59	0.2	16
340	Mood, Disability, and Quality of Life among a Subgroup of Rheumatoid Arthritis Individuals with Experiential Avoidance and Anxiety Sensitivity. <i>Pain Research and Management</i> , 2016 , 2016, 7241856	2.6	7
339	Psychological Distress in Out-Patients Assessed for Chronic Pain Compared to Those with Rheumatoid Arthritis. <i>Pain Research and Management</i> , 2016 , 2016, 7071907	2.6	6
338	Dispositional Affect in Unique Subgroups of Patients with Rheumatoid Arthritis. <i>Pain Research and Management</i> , 2016 , 2016, 1024985	2.6	4
337	Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016 , 9, 37-43	2.3	12
336	Dr. Roubille, et al reply. <i>Journal of Rheumatology</i> , 2016 , 43, 993-4	4.1	
335	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1195-200	4.7	23
334	Reply. <i>Arthritis Care and Research</i> , 2016 , 68, 1053-4	4.7	1
333	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. <i>RMD Open</i> , 2016 , 2, e000225	5.9	42
332	The Frequency of Scleroderma Renal Crisis over Time: A Metaanalysis. <i>Journal of Rheumatology</i> , 2016 , 43, 1350-5	4.1	27
331	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016 , 387, 2630-2640	4.0	359
330	Rheumatoid arthritis: TNF inhibitors and cardiovascular risk management in RA. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 317-8	8.1	3
329	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1975-88	27.4	74
328	Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study. <i>Rheumatology</i> , 2016 , 55, 2148-2155	3.9	39
327	Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1063-70	4.6	59
326	Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. <i>Clinical Rheumatology</i> , 2015 , 34, 1427-33	3.9	27

325	The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 692-6	3.9	16
324	The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015 , 120, 104-11	2	35
323	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015 , 42, 1156-62	4.1	4
322	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 680-6	5.3	43
321	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015 , 67, 1237-1245	4.7	67
320	Systemic sclerosis. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15002	51.1	351
319	Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e34	2.4	1
318	The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 499-505	5.3	7
317	Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 45, 184-9	5.3	18
316	Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. <i>Journal of Rheumatology</i> , 2015 , 42, 1767-80	4.1	88
315	Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2015 , 42, 2023-8	4.1	4
314	Health Literacy Rates in a Population of Patients with Rheumatoid Arthritis in Southwestern Ontario. <i>Journal of Rheumatology</i> , 2015 , 42, 1610-5	4.1	2
313	OP0054 Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 48 Data from the Fascinate Trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 87.2-88	2.4	8
312	2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2015 , 67, 582-7	4.7	51
311	Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2015 , 67, 616-23	4.7	20
310	Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. <i>Arthritis Care and Research</i> , 2015 , 67, 754-64	4.7	34
309	Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III. <i>Arthritis Care and Research</i> , 2015 , 67, 681-90	4.7	31
308	SAT0119 Prevalence of Cardiovascular Disease and its Associations with Disease Severity in Rheumatoid Arthritis Patients [Data from the Ontario Best Practices Research Initiative (OBRI)]. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 693.2-693	2.4	

307	Cervical spine involvement in rheumatoid arthritis over time: results from a meta-analysis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 148	5.7	37
306	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015 , 17, 343	5.7	9
305	Lessons learned from Canadian databases in RA, SLE and systemic sclerosis: highlights from the Canadian Rheumatology Association Annual Scientific Meeting. <i>International Journal of Clinical Rheumatology</i> , 2015 , 10, 135-137	1.5	
304	THU0337 Worse Disease Trajectory in Early RA Patients is Associated with Lower Improvements in Health Related Quality of Life; Results from a Multicenter Early RA Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 317.2-318	2.4	
303	Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada. <i>Arthritis Care and Research</i> , 2015 , 67, 1047-53	4.7	52
302	Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015 , 67, 1345-53	4.7	53
301	SAT0347 Comparisons of Reporting and Level of Agreement of Co-Morbidities Ascertained from Rheumatologists, Patients and Health Administrative Data: A Data Linkage Study Among Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 784.2-785	2.4	
300	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). <i>PLoS ONE</i> , 2015 , 10, e0135327	3.7	24
299	Drug interventions versus placebo for the treatment of Raynaud's phenomenon: generic protocol. <i>The Cochrane Library</i> , 2015 ,	5.2	2
298	Drug Treatment of Raynaud's Phenomenon 2015 , 315-337		
297	New Classification Criteria for Systemic Sclerosis (Scleroderma). <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 383-98	2.4	24
296	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015 , 42, 2512	4.1	3
295	Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a canadian multisite suspected rheumatoid arthritis inception cohort. <i>Journal of Rheumatology</i> , 2015 , 42, 46-54	4.1	15
294	The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 480-9	2.4	477
293	A comparison between general rheumatologists and scleroderma experts with respect to following systemic sclerosis guidelines. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S40-6	2.2	2
292	Social persuasion in rheumatology: a randomized trial of testimonials on television in the rheumatology clinic waiting room to increase attendance for multidisciplinary education. <i>Rheumatology International</i> , 2014 , 34, 903-7	3.6	5
291	A153: Long-term Outcomes of Childhood-Onset Systemic Lupus Erythematosus in Adulthood. <i>Arthritis and Rheumatology</i> , 2014 , 66, S198-S198	9.5	1
290	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2014 , 33, 207-14	3.9	43

289	Therapeutic drug monitoring in rheumatic diseases: utile or futile?. <i>Rheumatology</i> , 2014 , 53, 988-97	3.9	16
288	Lacunes dans la prise en charge de l'ostéoporose chez les patients atteints de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014 , 81, 413-417	0.1	
287	Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. <i>Journal of Rheumatology</i> , 2014 , 41, 2179-85	4.1	40
286	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1340-9	2.4	444
285	Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. <i>Journal of Rheumatology</i> , 2014 , 41, 270-9	4.1	61
284	RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1111-20	9.5	35
283	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 191-7	2.4	35
282	Response to: 'Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?' by Jan Damoiseaux. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e30	2.4	1
281	Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. <i>Journal of Rheumatology</i> , 2014 , 41, 1334-43	4.1	16
280	ImmunoChip analysis identifies multiple susceptibility loci for systemic sclerosis. <i>American Journal of Human Genetics</i> , 2014 , 94, 47-61	11	151
279	There is still a care gap in osteoporosis management for patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014 , 81, 347-51	2.9	11
278	Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. <i>Scandinavian Journal of Rheumatology</i> , 2014 , 43, 217-20	1.9	41
277	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 706-14	5.7	40
276	SAT0587 A Comparative Study of Rheumatology Specialist Training across UK and Canada. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 802.2-802	2.4	
275	FRI0371 A Comparison of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) TRIAL Design: Ways to Improve Positive Trials in Sle. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 521.1-521	2.4	
274	OP0200 Thromboembolism in Rheumatology: Investigation of the Risks of Deep Vein Thrombosis and Pulmonary Embolism in Inflammatory Arthritis, Connective Tissue Diseases, Vasculitis and Myositis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 138.2-138	2.4	
273	AB0251 The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) Serology on Outcomes in Early Rheumatoid Arthritis: Results from Catch (Canadian Early Arthritis Cohort). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 886.2-887	2.4	
272	The comparability of English, French and Dutch scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): an assessment of differential item functioning in patients with systemic sclerosis. <i>PLoS ONE</i> , 2014 , 9, e91979	3.7	10

271	THU0412 Cardiovascular Outcomes in Patients with Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analyses. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 324.2-325 ^{2,4}		
270	Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor. <i>PLoS ONE</i> , 2014 , 9, e100035	3.7	11
269	Association of health-related quality of life in childhood-onset systemic lupus erythematosus with ethnicity: results from a multiethnic multicenter Canadian cohort. <i>Arthritis Care and Research</i> , 2014 , 66, 1767-74	4.7	17
268	A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2014 , 16, 435	5.7	65
267	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014 , 16, 493	5.7	36
266	Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort. <i>Rheumatology</i> , 2014 , 53, 482-90	3.9	6
265	Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study. <i>Rheumatology</i> , 2014 , 53, 1830-4	3.9	6
264	Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 1653-61	4.7	104
263	Frailty index to measure health status in people with systemic sclerosis. <i>Journal of Rheumatology</i> , 2014 , 41, 698-705	4.1	35
262	The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2144-51	2.4	34
261	Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2361-9	4.1	49
260	Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. <i>Rheumatology</i> , 2014 , 53, 1075-86	3.9	23
259	Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH). <i>Journal of Rheumatology</i> , 2014 , 41, 2161-6	4.1	35
258	Comprehensive arthritis referral study -- phase 2: analysis of the comprehensive arthritis referral tool. <i>Journal of Rheumatology</i> , 2014 , 41, 1980-9	4.1	11
257	The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. <i>Rheumatology</i> , 2014 , 53, 1386-94	3.9	50
256	Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. <i>Journal of Rheumatology</i> , 2014 , 41, 792-8	4.1	36
255	Factors associated with time to diagnosis in early rheumatoid arthritis. <i>Rheumatology International</i> , 2014 , 34, 85-92	3.6	13
254	An assessment of the measurement equivalence of English and French versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in systemic sclerosis. <i>PLoS ONE</i> , 2014 , 9, e102897	3.7	9

253	Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor. <i>Open Rheumatology Journal</i> , 2014 , 8, 73-6	0.2	3
252	Estimating Benefits from Immunesuppressive Treatment in Diffuse Cutaneous Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2014 , 04, 248-253	0.2	1
251	Skin Manifestations and Musculoskeletal Disease in SSc 2014 , 23-36		
250	Prevalence of hearing loss in the United States by industry. <i>American Journal of Industrial Medicine</i> , 2013 , 56, 670-81	2.7	82
249	Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013 , 65, 353-61	4.7	130
248	Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. <i>Rheumatology International</i> , 2013 , 33, 1105-20	3.6	19
247	Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohort. <i>Rheumatology International</i> , 2013 , 33, 457-65	3.6	4
246	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2737-47		1636
245	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013 , 42, 130-5	15.5	194
244	Highly effective visible-light-induced H ₂ generation by single-layer 1T-MoS ₂ and a nanocomposite of few-layer 2H-MoS ₂ with heavily nitrogenated graphene. <i>Angewandte Chemie - International Edition</i> , 2013 , 52, 13057-61	16.4	378
243	Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1553-68	3.8	126
242	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1747-55	2.4	1109
241	Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. <i>Arthritis Care and Research</i> , 2013 , 65, 152-60	4.7	44
240	The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. <i>Journal of Rheumatology</i> , 2013 , 40, 1545-56	4.1	94
239	Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. <i>Arthritis Care and Research</i> , 2013 , 65, 1460-71	4.7	74
238	Does cigarette smoking mitigate the severity of skin disease in systemic sclerosis?. <i>Rheumatology International</i> , 2013 , 33, 943-8	3.6	12
237	Updated systemic sclerosis criteria improve disease classification. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013 , 74, 609-609	0.8	
236	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013 , 3,	3	82

235	All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. <i>Rheumatology</i> , 2013 , 52, 905-9	3.9	76
234	Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: data from the Canadian Scleroderma Research Group. <i>Journal of Rheumatology</i> , 2013 , 40, 447-54	4.1	14
233	Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. <i>Journal of Rheumatology</i> , 2013 , 40, 1259-67	4.1	32
232	The frequency of and associations with hospitalization secondary to lupus flares from the 1000 Faces of Lupus Canadian cohort. <i>Lupus</i> , 2013 , 22, 1341-8	2.6	21
231	Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 949-54	2.4	53
230	Ottawa, Ontario, Canada, February 13-16, 2013. <i>Journal of Rheumatology</i> , 2013 , 40, 950-1025	4.1	2
229	Systemic sclerosis in Canada's North American Native population: assessment of clinical and serological manifestations. <i>Journal of Rheumatology</i> , 2013 , 40, 1121-6	4.1	11
228	Prevalence of current, 12-month and lifetime major depressive disorder among patients with systemic sclerosis. <i>Rheumatology</i> , 2013 , 52, 669-75	3.9	26
227	Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis. <i>Cmaj</i> , 2013 , 185, E70-7	3.5	8
226	Association of smoking with cutaneous manifestations in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2013 , 65, 1275-80	4.7	51
225	Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists. <i>Arthritis Care and Research</i> , 2013 , 65, 1582-91	4.7	61
224	Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. <i>Arthritis Care and Research</i> , 2013 , 65, 1401-9	4.7	29
223	Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. <i>Journal of Rheumatology</i> , 2013 , 40, 850-8	4.1	43
222	Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2013 , 40, 1823-30	4.1	24
221	OP0257 IL-6 in scleroderma; potential implications for targeted therapy: A systematic analysis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 143.1-143	2.4	
220	FRI0241 Association of gastroesophageal factors and progression of interstitial lung disease in the Canadian scleroderma research group (CSRG); a large, multi-center database. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 395.3-396	2.4	1
219	FRI0187 The effectiveness of abatacept in a large RA real world database including durability and changes in haq over time: Post DMARDs and post TNF. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 375.3-376	2.4	6
218	SAT0101 Das does not predict increasing treatment in early rheumatoid arthritis (ERA): Results from the catch study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 504.2-504	2.4	

217	Cross-language measurement equivalence of the Center for Epidemiologic Studies Depression (CES-D) scale in systemic sclerosis: a comparison of Canadian and Dutch patients. <i>PLoS ONE</i> , 2013 , 8, e53923	3.7	12
216	The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28 Varies Over Time and by Rheumatoid Factor Status in Early Inflammatory Arthritis (EIA). Results from the CATCH Cohort. <i>Open Rheumatology Journal</i> , 2013 , 7, 58-63	0.2	14
215	Raynaud's phenomenon (primary). <i>Clinical Evidence</i> , 2013 , 2013, 1119		6
214	Systemic Sclerosis 2013 , 955-969		1
213	A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 24-30	2.2	6
212	The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 122-34	2.2	28
211	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012 , 64, 351-7	4.7	41
210	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012 , 64, 358-67	4.7	64
209	Rates and correlates of sexual activity and impairment among women with systemic sclerosis. <i>Arthritis Care and Research</i> , 2012 , 64, 340-50	4.7	14
208	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012 , 51, 2204-14	3.9	102
207	Longitudinal study of renal function in systemic sclerosis. <i>Journal of Rheumatology</i> , 2012 , 39, 1829-34	4.1	16
206	Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. <i>Journal of Rheumatology</i> , 2012 , 39, 1120-4	4.1	29
205	Effect of rheumatologist education on systematic measurements and treatment decisions in rheumatoid arthritis: the metrix study. <i>Journal of Rheumatology</i> , 2012 , 39, 2247-52	4.1	11
204	Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort. <i>Journal of Rheumatology</i> , 2012 , 39, 2088-97	4.1	26
203	Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2012 , 64, 1405-14	4.7	72
202	Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3420-9		57
201	Issues in Clinical Trial Design 2012 , 651-660		
200	Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 42-55	5.3	91

199	Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 179-85	5.3	93
198	Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 271-80	5.3	36
197	Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. <i>Journal of Rheumatology</i> , 2012 , 39, 524-31	4.1	28
196	Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R50	5.7	80
195	Sociodemographic and disease correlates of body image distress among patients with systemic sclerosis. <i>PLoS ONE</i> , 2012 , 7, e33281	3.7	34
194	Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. <i>Arthritis Care and Research</i> , 2012 , 64, 519-24	4.7	87
193	Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. <i>Arthritis Care and Research</i> , 2012 , 64, 955-9	4.7	2
192	Influence of somatic symptoms on Patient Health Questionnaire-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. <i>Arthritis Care and Research</i> , 2012 , 64, 1195-201	4.7	14
191	Corticosteroids and the risk of scleroderma renal crisis: a systematic review. <i>Rheumatology International</i> , 2012 , 32, 645-53	3.6	52
190	Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2012 , 39, 787-94	4.1	34
189	The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. <i>Journal of Rheumatology</i> , 2012 , 39, 2071-80	4.1	35
188	Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis. <i>Journal of Rheumatology</i> , 2012 , 39, 1221-30	4.1	53
187	Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study. <i>Journal of Rheumatology</i> , 2012 , 39, 2081-7	4.1	10
186	Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. <i>Journal of Rheumatology</i> , 2012 , 39, 1583-602	4.1	104
185	Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. <i>Journal of Rheumatology</i> , 2012 , 39, 1559-82	4.1	169
184	Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 1378-84	4.1	15
183	Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. <i>Rheumatology</i> , 2012 , 51, 1662-9	3.9	35
182	Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria. <i>Journal of Rheumatology</i> , 2012 , 39, 1155-8	4.1	30

181	The sensitivity and specificity of pain diagrams in rheumatic disease referrals. <i>Rheumatology</i> , 2012 , 51, 1093-8	3.9	4
180	Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial. <i>Medical Science Monitor</i> , 2012 , 18, PI17-20	3.2	2
179	Sexual activity and impairment in women with systemic sclerosis compared to women from a general population sample. <i>PLoS ONE</i> , 2012 , 7, e52129	3.7	15
178	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S23-9	2.2	26
177	Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG). <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S38-43	2.2	11
176	Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. <i>Clinica Chimica Acta</i> , 2011 , 412, 1937-43	6.2	30
175	Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 635-62	3.8	135
174	Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. <i>Journal of Rheumatology</i> , 2011 , 38, 2095-104	4.1	8
173	A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. <i>Genes and Immunity</i> , 2011 , 12, 51-8	4.4	36
172	Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 81-9	5.3	33
171	Treatment of early rheumatoid arthritis: concepts in management. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 40, 371-88	5.3	30
170	Anti-fibrillar antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. <i>Journal of Rheumatology</i> , 2011 , 38, 1622-30	4.1	31
169	Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. <i>Arthritis Care and Research</i> , 2011 , 63, 53-7	4.7	39
168	Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. <i>Arthritis Care and Research</i> , 2011 , 63, 142-9	4.7	97
167	Modeling smoking in systemic sclerosis: a comparison of different statistical approaches. <i>Arthritis Care and Research</i> , 2011 , 63, 570-8	4.7	11
166	Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GI) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Atkade Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Basaud's Condition Score (CS). <i>Arthritis Care and Research</i> , 2011 , 63 Suppl 11, S98-111	4.7	74
165	Cigarette smoking in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 230-8		59
164	Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1479-85		111

163	Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3547-51		87
162	Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial. <i>Scandinavian Journal of Rheumatology</i> , 2011 , 40, 232-3	1.9	4
161	Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. <i>Journal of Rheumatology</i> , 2011 , 38, 1326-8	4.1	44
160	Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. <i>Lupus</i> , 2011 , 20, 1345-55	2.6	108
159	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 32-8	2.4	304
158	Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 1996-2003	4.3	62
157	Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. <i>Journal of Rheumatology</i> , 2011 , 38, 658-66	4.1	27
156	Measuring pain in systemic sclerosis: comparison of the short-form McGill Pain Questionnaire versus a single-item measure of pain. <i>Journal of Rheumatology</i> , 2011 , 38, 2581-7	4.1	10
155	Self-reported flaring varies during the menstrual cycle in systemic lupus erythematosus compared with rheumatoid arthritis and fibromyalgia. <i>Rheumatology</i> , 2011 , 50, 703-8	3.9	21
154	Disability in systemic sclerosis -- a longitudinal observational study. <i>Journal of Rheumatology</i> , 2011 , 38, 685-92	4.1	29
153	Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. <i>Rheumatology</i> , 2011 , 50, 311-6	3.9	41
152	Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. <i>Rheumatology</i> , 2011 , 50, 762-7	3.9	145
151	Medication use in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2011 , 38, 271-4	4.1	10
150	Observational data to study medication outcomes in systemic sclerosis. <i>Journal of Rheumatology</i> , 2011 , 38, 575-7	4.1	1
149	Clinical correlates of sleep problems in systemic sclerosis: the prominent role of pain. <i>Rheumatology</i> , 2011 , 50, 921-5	3.9	20
148	The association of body image dissatisfaction and pain with reduced sexual function in women with systemic sclerosis. <i>Rheumatology</i> , 2011 , 50, 1125-30	3.9	20
147	Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort. <i>Journal of Rheumatology</i> , 2011 , 38, 2342-5	4.1	13
146	Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. <i>Journal of Rheumatology</i> , 2011 , 38, 1925-30	4.1	23

145	A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. <i>Medical Science Monitor</i> , 2011 , 17, CR347-54	3.2	85
144	Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves. <i>ISRN Rheumatology</i> , 2011 , 2011, 580704		4
143	A Middle-Aged Male Scleroderma Patient Who Can No Longer Perform His Occupation 2011 , 281-292		
142	The association between disease activity and duration in systemic sclerosis. <i>Journal of Rheumatology</i> , 2010 , 37, 2299-306	4.1	6
141	Discordance between patient and physician assessments of disease severity in systemic sclerosis. <i>Journal of Rheumatology</i> , 2010 , 37, 2307-12	4.1	25
140	The minimally important difference for patient-reported outcomes in spondyloarthropathies including pain, fatigue, sleep, and Health Assessment Questionnaire. <i>Journal of Rheumatology</i> , 2010 , 37, 816-22	4.1	22
139	Clinical and serologic factors associated with lupus pleuritis. <i>Journal of Rheumatology</i> , 2010 , 37, 747-53	4.1	23
138	Altered salivary redox homeostasis in patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2010 , 37, 1858-63	4.1	10
137	Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). <i>Rheumatology</i> , 2010 , 49, 1683-93	3.9	135
136	Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. <i>Journal of Rheumatology</i> , 2010 , 37, 1024-8	4.1	45
135	The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations. <i>Rheumatology</i> , 2010 , 49, 1616-7	3.9	4
134	Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. <i>Rheumatology</i> , 2010 , 49, 2172-80	3.9	109
133	Care gap in patients with early inflammatory arthritis with a high fracture risk identified using FRAX(®). <i>Journal of Rheumatology</i> , 2010 , 37, 2221-5	4.1	17
132	Social responsibility of hospitals: an Indian context. <i>Social Responsibility Journal</i> , 2010 , 6, 268-285	3	25
131	The chemokine CCL18 generates adaptive regulatory T cells from memory CD4+ T cells of healthy but not allergic subjects. <i>FASEB Journal</i> , 2010 , 24, 5063-72	0.9	31
130	Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. <i>Journal of Rheumatology</i> , 2010 , 37, 2469-74	4.1	12
129	Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan. <i>Annals of the Rheumatic Diseases</i> , 2010 69, 2055-6	2.4	10
128	The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma. <i>Journal of Rheumatology</i> , 2010 , 37, 591-8	4.1	44

127	The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 87-90	4.1	9
126	Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal consistency reliability, convergent validity and clinical correlates. <i>Rheumatology</i> , 2010 , 49, 789-96	3.9	91
125	Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 1422-30	4.1	29
124	Is serum albumin a marker of malnutrition in chronic disease? The scleroderma paradigm. <i>Journal of the American College of Nutrition</i> , 2010 , 29, 144-51	3.5	21
123	Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. <i>Journal of Rheumatology</i> , 2010 , 37, 38-44	4.1	81
122	Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16 Suppl 1, S27-34	3	16
121	What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). <i>Rheumatology International</i> , 2010 , 30, 1205-10	3.6	15
120	Determinants of morbidity and mortality of systemic sclerosis in Canada. <i>Seminars in Arthritis and Rheumatism</i> , 2010 , 39, 269-77	5.3	142
119	Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2010 , 62, 409-17	4.7	56
118	Sexual function in women with systemic sclerosis: Comment on the article by Schouffoer et al. <i>Arthritis Care and Research</i> , 2010 , 62, 1200; author reply 1200-1	4.7	
117	Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. <i>Arthritis Care and Research</i> , 2010 , 62, 1181-9	4.7	66
116	Association of pruritus with quality of life and disability in systemic sclerosis. <i>Arthritis Care and Research</i> , 2010 , 62, 1489-95	4.7	35
115	Development and validation of the brief-satisfaction with appearance scale for systemic sclerosis. <i>Arthritis Care and Research</i> , 2010 , 62, 1779-86	4.7	31
114	Demographic and clinical factors associated with physician service use in systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 96-8	4.1	5
113	The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. <i>Journal of Rheumatology</i> , 2009 , 36, 1200-8	4.1	92
112	The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. <i>Rheumatology</i> , 2009 , 48, 791-5	3.9	36
111	Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. <i>Lupus</i> , 2009 , 18, 1281-8	2.6	62
110	Validity of self-reported comorbidities in systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 1477-80	4.1	3

109	Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 2178-82	4.1	44
108	Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil. <i>Journal of Rheumatology</i> , 2009 , 36, 460-2	4.1	10
107	Clinical correlates of self-reported physical health status in systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 1226-9	4.1	16
106	Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. <i>Journal of Rheumatology</i> , 2009 , 36, 1421-8	4.1	33
105	Association of severe inflammatory polyarthritis in primary Sjögren's syndrome: clinical, serologic, and HLA analysis. <i>Journal of Rheumatology</i> , 2009 , 36, 1937-42	4.1	15
104	The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. <i>Journal of Rheumatology</i> , 2009 , 36, 2231-7	4.1	51
103	Quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions. <i>Journal of Rheumatology</i> , 2009 , 36, 768-72	4.1	54
102	Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. <i>Journal of Rheumatology</i> , 2009 , 36, 2737-43	4.1	90
101	(Not) talking about sex: a systematic comparison of sexual impairment in women with systemic sclerosis and other chronic disease samples. <i>Rheumatology</i> , 2009 , 48, 1300-3	3.9	33
100	Work disability in systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 2481-6	4.1	48
99	Requirement of transforming growth factor beta-activated kinase 1 for transforming growth factor beta-induced alpha-smooth muscle actin expression and extracellular matrix contraction in fibroblasts. <i>Arthritis and Rheumatism</i> , 2009 , 60, 234-41		63
98	Time to diagnosis in systemic sclerosis: is sex a factor?. <i>Arthritis and Rheumatism</i> , 2009 , 61, 274-8		22
97	MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 870-7		89
96	Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients. <i>Arthritis and Rheumatism</i> , 2009 , 61, 966-73		48
95	Health-related quality of life in systemic sclerosis: a systematic review. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1112-20		97
94	Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1765-70		26
93	The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. <i>Journal of Rheumatology</i> , 2009 , 36, 254-9	4.1	98
92	Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 402-11	4.5	33

91	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon 2009 , 77-95		
90	Potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario. <i>Scandinavian Journal of Rheumatology</i> , 2009 , 38, 390-1	1.9	2
89	Epidemiologic approaches to infection and immunity: the case of reactive arthritis. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 386-90	5.3	13
88	Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. <i>Journal of Rheumatology</i> , 2009 , 36, 323-9	4.1	57
87	Reports of abnormal cervical cancer screening tests in systemic sclerosis. <i>Rheumatology</i> , 2009 , 48, 149-51.	3.9	20
86	Employment and work disability in systemic lupus erythematosus: a systematic review. <i>Rheumatology</i> , 2009 , 48, 281-4	3.9	96
85	The cost of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 119-23		50
84	Digital ulcers: overt vascular disease in systemic sclerosis. <i>Rheumatology</i> , 2009 , 48 Suppl 3, iii19-24	3.9	106
83	Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity. <i>Arthritis Research and Therapy</i> , 2008 , 10, R108	5.7	34
82	Polyautoimmunity and familial autoimmunity in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2008 , 31, 156-9	15.5	83
81	Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. <i>Journal of Clinical Epidemiology</i> , 2008 , 61, 654-62	5.7	8
80	A randomized trial of arthroscopic surgery for osteoarthritis of the knee. <i>New England Journal of Medicine</i> , 2008 , 359, 1097-107	59.2	483
79	Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. <i>Rheumatology</i> , 2008 , 47, 1367-72	3.9	15
78	An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it?. <i>Lupus</i> , 2008 , 17, 274-7	2.6	54
77	The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. <i>Journal of Rheumatology</i> , 2008 , 35, 2339-43	4.1	72
76	The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 2329-33	4.1	8
75	A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008 , 27, 77-83	3.9	71
74	High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. <i>Arthritis and Rheumatism</i> , 2008 , 59, 431-7		17

73	Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 438-43		63
72	Quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008 , 59, 270-8		64
71	Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008 , 59, 279-84		41
70	Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 504-9		72
69	Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. <i>Arthritis and Rheumatism</i> , 2008 , 59, 706-13		10
68	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 867-75		45
67	Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1796-804		107
66	Assessment of reproductive history in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1661-4		7
65	Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1222-8	2.4	98
64	Development of a provisional core set of response measures for clinical trials of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 703-9	2.4	65
63	Arthritis risk after acute bacterial gastroenteritis. <i>Rheumatology</i> , 2008 , 47, 200-4	3.9	36
62	The relationship of dyspnoea to function and quality of life in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 644-50	2.4	24
61	Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores. <i>Open Rheumatology Journal</i> , 2008 , 2, 44-52	0.2	26
60	The relationship between NSAID use and osteoarthritis (OA) severity in patients with hip and knee OA: results of a case control study of NSAID use comparing those requiring hip and knee replacements to those in whom surgery was not recommended. <i>Medical Science Monitor</i> , 2008 , 14, CR604-10	3.2	7
59	The diagnosis and treatment of Raynaud's phenomenon: a practical approach. <i>Drugs</i> , 2007 , 67, 517-25	12.1	92
58	Campylobacter reactive arthritis: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2007 , 37, 48-55	5.3	130
57	Update on indices of disease activity in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2007 , 37, 93-8	5.3	48
56	Office capillaroscopy in systemic sclerosis. <i>Clinical Rheumatology</i> , 2007 , 26, 1268-74	3.9	53

55	The development of systemic sclerosis classification criteria. <i>Clinical Rheumatology</i> , 2007 , 26, 1401-9	3.9	45
54	Psoriasis and pustular dermatitis triggered by TNF- α inhibitors in patients with rheumatologic conditions. <i>Archives of Dermatology</i> , 2007 , 143, 223-31		219
53	CIP2A inhibits PP2A in human malignancies. <i>Cell</i> , 2007 , 130, 51-62	56.2	591
52	SEQUENCE OF VARIABLES IN THE DIMENSIONAL SET 2007 , 381-400		
51	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007 , 34, 501-9	4.1	38
50	Systemic sclerosis - continuing progress in developing clinical measures of response. <i>Journal of Rheumatology</i> , 2007 , 34, 1194-200	4.1	58
49	Scleroderma treatment differs between experts and general rheumatologists. <i>Arthritis and Rheumatism</i> , 2006 , 55, 138-45		19
48	Mortality in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2550-7		751
47	Convergence paralysis as a manifestation of polyarteritis nodosa. <i>Canadian Journal of Neurological Sciences</i> , 2006 , 33, 423-5	1	1
46	Mortality related to cerebrovascular disease in systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 835-9	2.6	57
45	A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water. <i>Journal of Clinical Epidemiology</i> , 2006 , 59, 421-8	5.7	33
44	Other manifestations of mixed connective tissue disease. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 519-33, vii	2.4	38
43	Osteoporosis in scleroderma. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 34, 678-82	5.3	42
42	An international cohort study of cancer in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1481-90		292
41	Race/ethnicity and cancer occurrence in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005 , 53, 781-4		44
40	Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. <i>Rheumatology</i> , 2005 , 44, 145-50	3.9	155
39	Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2005 , 32, 1273-8	4.1	55
38	The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. <i>British Journal of Rheumatology</i> , 2004 , 43, 472-8		23

37	Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3985-93		533
36	Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. <i>Arthritis and Rheumatism</i> , 2004 , 51, 738-45		109
35	Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004 , 31, 508-13	4.1	39
34	Treatment of osteoarthritis of the hip and knee: a comparison of NSAID use in patients for whom surgery was and was not recommended. <i>Clinical and Experimental Rheumatology</i> , 2004 , 22, 171-6	2.2	1
33	Frequency of adverse drug reactions (ADRS) in SLE. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, P54-P54	6.1	
32	Musculoskeletal involvement in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2003 , 29, 391-408	4.1	39
31	Frequency of adverse drug reactions in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003 , 30, 480-4	4.1	33
30	Raynaud's phenomenon (primary). <i>Clinical Evidence</i> , 2003 , 1339-48		2
29	A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. <i>Osteoarthritis and Cartilage</i> , 2002 , 10, 518-27	6.2	78
28	A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. <i>Osteoarthritis and Cartilage</i> , 2002 , 10, 506-17	6.2	153
27	Scleroderma overlap syndromes. <i>Current Opinion in Rheumatology</i> , 2002 , 14, 704-10	5.3	47
26	Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. <i>Journal of Clinical Epidemiology</i> , 2002 , 55, 488-97	5.7	41
25	Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. <i>Journal of Rheumatology</i> , 2002 , 29, 255-60	4.1	31
24	Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. <i>Journal of Rheumatology</i> , 2002 , 29, 1867-73	4.1	38
23	A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1351-8		302
22	Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1841-7		206
21	Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. <i>The Cochrane Library</i> , 2000 , CD000953	5.2	35
20	Measurement in Scleroderma Clinical Trials 2000 , 183-203		

19	The frequency and significance of anticardiolipin antibodies in scleroderma. <i>Journal of Rheumatology</i> , 2000 , 27, 1450-2	4.1	16
18	A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. <i>Journal of Rheumatology</i> , 2000 , 27, 1506-12	4.1	22
17	The lack of associations between rheumatoid arthritis and both nulliparity and infertility. <i>Seminars in Arthritis and Rheumatism</i> , 1999 , 28, 342-50	5.3	29
16	Antimitochondrial antibodies and their significance in diffuse and limited scleroderma. <i>Journal of Clinical Rheumatology</i> , 1999 , 5, 206-9	1.1	10
15	A study of the frequency of pericardial and pleural effusions in scleroderma. <i>British Journal of Rheumatology</i> , 1998 , 37, 1320-3		60
14	A randomized double blind trial of verbal NSAID education compared to verbal and written education. <i>Journal of Rheumatology</i> , 1998 , 25, 771-5	4.1	11
13	The development of rheumatoid arthritis after recombinant hepatitis B vaccination. <i>Journal of Rheumatology</i> , 1998 , 25, 1687-93	4.1	65
12	Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. <i>New England Journal of Medicine</i> , 1997 , 337, 382-7	59.2	608
11	Treatment of systemic sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 1996 , 22, 893-907	2.4	14
10	Increased pigmentation in scleroderma. <i>Journal of Rheumatology</i> , 1996 , 23, 1912-6	4.1	11
9	Variability of skin scores and clinical measurements in scleroderma. <i>Journal of Rheumatology</i> , 1995 , 22, 1271-6	4.1	48
8	Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. <i>Clinical and Investigative Medicine</i> , 1995 , 18, 1-10	0.9	3
7	Treatment of systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 1993 , 5, 792-801	5.3	11
6	Outcome measurement in scleroderma clinical trials. <i>Seminars in Arthritis and Rheumatism</i> , 1993 , 23, 22-33	5.3	36
5	A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. <i>Archives of Internal Medicine</i> , 1993 , 153, 477-484		84
4	Early intensive treatment of clubfoot. 75 feet followed for 6-11 years. <i>Acta Orthopaedica</i> , 1992 , 63, 183-8		17
3	Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. <i>American Journal of Medicine</i> , 1991 , 90, 299-309	2.4	59
2	Renal calcification 276-281		

1 Systemic Sclerosis443-493